Inventiva (IVA) Stock Overview

A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. More details

IVA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	3/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Rewards

Revenue is forecast to grow 53.19% per year

Risk Analysis

Negative shareholders equity

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

IVA Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW466,074 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

466,074 investors already sharing narratives

View all narratives

Inventiva S.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Inventiva
Historical stock prices
Current Share Price	€4.68
52 Week High	€7.98
52 Week Low	€3.35
Beta	0.91
1 Month Change	4.93%
3 Month Change	-7.69%
1 Year Change	4.58%
3 Year Change	37.24%
5 Year Change	-62.74%
Change since IPO	-65.13%

Recent News & Updates

Seeking Alpha • Aug 05

Inventiva: MASH Is Becoming A Combination Market Before Lanifibranor Arrives

Summary Inventiva is positioned as a high-risk, clinical catalyst play targeting MASH with its oral pan-PPAR agonist, lanifibranor. Lanifibranor's potential lies in combination therapy, offering dual metabolic and anti-fibrotic benefits independent of weight loss, complementing GLP-1 and SGLT2 agents. Inventiva has secured sufficient liquidity through Q2 2027, with contingent access to further capital, and has strengthened governance ahead of the pivotal NATiV3 Phase 3 readout. NATiV3 results in Q4 2026 are the defining catalyst; success could secure lanifibranor a differentiated and versatile role in the evolving MASH treatment landscape. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Aug 05

Inventiva: MASH Is Becoming A Combination Market Before Lanifibranor Arrives

Seeking Alpha • Jul 08

Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement

Summary Inventiva S.A. top-line results from phase 3 NATiV3 study, using lanifibranor for the treatment of patients with MASH, expected by 2nd half of 2026. The 4th pass of the safety review of the DMC was conducted, and it was noted that the phase 3 NATiV3 study should continue without modification. The global non-alcoholic steatohepatitis market is expected to reach $48.3 billion by the end of 2035. It could compete against other MASH companies with the use of lanifibranor by establishing several competitive advantages or by combining it with GLP-1 drugs. Read the full article on Seeking Alpha

Seeking Alpha • Feb 22

Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause

Summary Enrollment pause in phase III NATiV3 study, using lanifibranor for the treatment of patients with NASH, only expected to last 4 to 6 weeks; Trial to continue on with protocol amendments. Publication of results from phase IIa LEGEND study, using lanifibranor in combination with Jardiance for the treatment of patients with NASH and Type 2 Diabetes, expected Q1 of 2024. The global non-alcoholic steatohepatitis treatment market size is expected to reach $48.3 billion by the end of 2035. Several competitors in NASH, but the company might overcome most with the fact that oral administration can be given; Another option to beat the competition would be through combination treatments such as lanifibranor + Jardiance. Read the full article on Seeking Alpha

Seeking Alpha • Sep 21

Inventiva, Sino Biopharm sign licensing pact to develop, commercialize NASH treatment

France-based clinical-stage biopharma Inventiva (NASDAQ:IVA) on Wednesday said it had entered into a licensing and collaboration agreement with a unit of Chinese pharmaceutical group Sino Biopharm for its non-alcoholic steatohepatitis (NASH) treatment lanifibranor. As per the deal, Inventiva (IVA) will get a $12M upfront payment along with $5M in short term potential milestone payments. IVA will also be eligible to get up to $290M in clinical, regulatory and commercial milestone payments, in addition to tiered royalties. Sino Biopharm will oversee the development and commercialization of lanifibranor in Greater China, IVA said in a statement. IVA's lanifibranor had previously received a breakthrough therapy designation from the U.S. FDA. U.S.-listed shares of IVA -2.8% to $3.82 after hours.

Shareholder Returns

	IVA	US Biotechs	US Market
7D	1.7%	7.1%	-1.5%
1Y	4.6%	45.3%	17.8%

Return vs Industry: IVA underperformed the US Biotechs industry which returned 45.3% over the past year.

Return vs Market: IVA underperformed the US Market which returned 17.8% over the past year.

Price Volatility

Is IVA's price volatile compared to industry and market?
IVA volatility
IVA Average Weekly Movement	9.4%
Biotechs Industry Average Movement	9.9%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

Stable Share Price: IVA has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: IVA's weekly volatility (9%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2011	73	Andrew Obenshain	inventivapharma.com

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis.

Inventiva S.A. Fundamentals Summary

How do Inventiva's earnings and revenue compare to its market cap?
IVA fundamental statistics
Market cap	US$1.11b
Earnings (TTM)	-US$413.57m
Revenue (TTM)	US$7.90m

140.5x

P/S Ratio

-2.7x

P/E Ratio

Is IVA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IVA income statement (TTM)
Revenue	€6.76m
Cost of Revenue	€22.00k
Gross Profit	€6.74m
Other Expenses	€360.88m
Earnings	-€354.14m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

Sep 25, 2026

Earnings per share (EPS)	-1.50
Gross Margin	99.67%
Net Profit Margin	-5,237.95%
Debt/Equity Ratio	-799.8%

How did IVA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/08/23 02:48
End of Day Share Price	2026/08/21 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Inventiva S.A. is covered by 24 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Eliana Merle	Barclays
Edward Nash	Canaccord Genuity
Prakhar Agrawal	Cantor Fitzgerald & Co.

Inventiva (IVA) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Inventiva S.A. Competitors

Immatics

Neurogene

Sana Biotechnology

CytomX Therapeutics

Price History & Performance

Recent News & Updates

Inventiva: MASH Is Becoming A Combination Market Before Lanifibranor Arrives

Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $119.999999 million.

Inventiva S.A. announced that it expects to receive €130 million in funding from BlackRock, Inc., Claret Capital Partners Limited

Inventiva S.A., Annual General Meeting, Jun 30, 2026

Inventiva Announces Executives Changes

Inventiva S.A. to Report Fiscal Year 2025 Results on Mar 30, 2026

Recent updates

Inventiva: MASH Is Becoming A Combination Market Before Lanifibranor Arrives

Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $119.999999 million.

Inventiva S.A. announced that it expects to receive €130 million in funding from BlackRock, Inc., Claret Capital Partners Limited

Inventiva S.A., Annual General Meeting, Jun 30, 2026

Inventiva Announces Executives Changes

Inventiva S.A. to Report Fiscal Year 2025 Results on Mar 30, 2026

Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $149.999996 million.

Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $125 million.

Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $100 million.

Inventiva Announces CEO Changes

Inventiva Announces Executive Appointments

Inventiva Announces the Publication in Journal of Hepatology Reports on Results of Lanifibranor Treatment on Liver Sinusoidal Endothelial Cells in Patients with MASLD/MASH and in Preclinical Models of the Disease

Inventiva Announces the Appointment of Renée Aguiar-Lucander to Its Board of Directors

Inventiva Announces the Publication in Clinical Gastroenterology and Hepatology of Its Analysis of New Biomarker Signatures Predictive of Histological Response in Patients with Mash Treated with Lanifibranor

Inventiva S.A., Annual General Meeting, May 22, 2025

Inventiva S.A. and Hepalys Pharma, Inc. Announce the Initiation of the Clinical Development Program of Lanifibranor in Japan

Inventiva S.A. to Report First Half, 2025 Results on Sep 25, 2025

Inventiva to Present Data from the Final Analysis of the Phase 2 Study Evaluating the Combination of Lanifibranor with Empagliflozin in Patients with Mash and T2d At the Aasld the Liver Meeting® Late-Breaker Session

Inventiva Announces the Positive Recommendation of the Fifth DMC of the Nativ3 Phase 3 Clinical Trial with Lanifibranor in Patients with Mash

Inventiva S.A. announced that it expects to receive €348 million in funding from a group of investors

Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement

Inventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with Lanifibranor

Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause

Inventiva S.A. Provides Update on its Clinical Trial NATiV3

Inventiva S.A. to Report First Half, 2024 Results on Sep 25, 2024

Inventiva Announces the Randomization of the First Patient in China in the NATiV3 Clinical Trial and Provides an Update on Its Clinical Development Program

Inventiva S.A. to Report Fiscal Year 2023 Results on Mar 27, 2024

Inventiva S.A. to Report Nine Months, 2023 Results on Sep 28, 2023

Inventiva Announces Positive Topline Results from the Investigator-Initiated Phase Ii Clinical Trial Evaluating Lanifibranor in Patients with T2d and NAFLD

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva, Sino Biopharm sign licensing pact to develop, commercialize NASH treatment

Shareholder Returns

Price Volatility

About the Company

Inventiva S.A. Fundamentals Summary

Earnings & Revenue

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources